Yongkang Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yongkang Zhang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Yemin Cao
Diagnosis and Treatment Center of Vascular Disease, Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
4 shared publications Fang Cao
2 shared publicationsJiaruo Xu
Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine
2 shared publicationsAoshuang Li
Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100053, China
1 shared publication- Heng-Wen Chen
Guang’anmen Hospital, China Academy of Chinese Medical Sciences
1 shared publication Hongcheng Du
Pan-Vascular Management Center, Shanghai TCM-Integrative Hospital, Shanghai University of Traditional Chinese Medicine
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1916929
From revascularization to multimodal integrated therapy for peripheral arterial disease: immunomodulation, metabolic correction, and tissue engineering
Peripheral arterial disease (PAD), a critical manifestation of systemic atherosclerosis (AS), poses substantial therapeutic challenges. Despite pharmacological interventions and revascularization, efficacy remains constrained by high restenosis rates and suboptimal functional recovery. These limitations underscore a necessary transition from localized structural revascularization toward integrated systemic repair, with a particular focus on the underlying immunopathology. The progression of PAD is driven by a dysregulated immune response, characterized by an imbalance in macrophage polarization (M1/M2), overactivation of the NLRP3 inflammasome, and a vicious cycle of immune-metabolic coupling. Current research trajectories emphasize the synergistic orchestration of the vascular microenvironment through immunomodulation. Beyond modulating localized inflammatory responses, emerging strategies target metabolic homeostasis and advanced tissue engineering, including spatiotemporal growth factor delivery, extracellular vesicle-based therapies, and bioengineered scaffolding systems. These interdisciplinary developments point toward a multimodal integrated therapeutic strategy for PAD. Such a strategy would build on conventional revascularization and may address its limitations, including restenosis, through targeted immunomodulation and local tissue regeneration. Whether this approach can improve long-term outcomes compared with revascularization alone remains to be tested. If validated, it could shift the clinical standard beyond vessel patency toward comprehensive, long-term vascular health.
- 22 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1916929
Open AccessFrom revascularization to multimodal integrated therapy for peripheral arterial disease: immunomodulation, metabolic correction, and tissue engineering
Peripheral arterial disease (PAD), a critical manifestation of systemic atherosclerosis (AS), poses substantial therapeutic challenges. Despite pharmacological interventions and revascularization, efficacy remains constrained by high restenosis rates and suboptimal functional recovery. These limitations underscore a necessary transition from localized structural revascularization toward integrated systemic repair, with a particular focus on the underlying immunopathology. The progression of PAD is driven by a dysregulated immune response, characterized by an imbalance in macrophage polarization (M1/M2), overactivation of the NLRP3 inflammasome, and a vicious cycle of immune-metabolic coupling. Current research trajectories emphasize the synergistic orchestration of the vascular microenvironment through immunomodulation. Beyond modulating localized inflammatory responses, emerging strategies target metabolic homeostasis and advanced tissue engineering, including spatiotemporal growth factor delivery, extracellular vesicle-based therapies, and bioengineered scaffolding systems. These interdisciplinary developments point toward a multimodal integrated therapeutic strategy for PAD. Such a strategy would build on conventional revascularization and may address its limitations, including restenosis, through targeted immunomodulation and local tissue regeneration. Whether this approach can improve long-term outcomes compared with revascularization alone remains to be tested. If validated, it could shift the clinical standard beyond vessel patency toward comprehensive, long-term vascular health.
- Open Access
- 18 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1762892
Global perspectives on lupus nephritis: a review of clinical trials and therapeutic innovations
Background and objectives: Lupus nephritis (LN) remains a leading cause of morbidity and mortality in systemic lupus erythematosus (SLE). Although recent years have witnessed the approval of several targeted therapies, achieving long-term, drug-free remission remains challenging. This commentary evaluates the global landscape of interventional LN clinical trials from 2001 to 2026 to identify emerging trends and strategic gaps in drug development. Methods: We analyzed 200 interventional pharmacological trials retrieved from three major global registries: ClinicalTrials.gov , Chinadrugtrials.org , and ISRCTN. Trials were systematically categorized by study phase, geographic distribution, and therapeutic mechanism, with data synthesized to reflect the transition from non-specific immunosuppression to precision-targeted approaches. Key findings: Our analysis indicates an accelerating trend in Phase II/III trials, with a notable geographic shift toward the Asia-Pacific region. We identify a diversification of therapeutic targets beyond B-cell depletion (e.g., obinutuzumab) to include complement inhibitors, intracellular signaling blockers (BTK and JAK inhibitors), and novel immune-reset strategies such as CAR-T therapy. Despite these innovations, complete renal response rates in pivotal trials often plateau at 40-50%, suggesting a persistent “ceiling effect”. Conclusion and implications: To break current therapeutic plateaus, future research must prioritize: (1) integrating pharmacogenomics (e.g., CYP3A5 and TPMT genotyping) for personalized drug selection; (2) developing steroid-fast-tapering or steroid-free induction protocols to minimize toxicity; and (3) validating real-time molecular biomarkers to replace lagging clinical indicators. This data-driven perspective provides a practical framework for refining trial designs and achieving precision medicine in LN.
- 18 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1762892
Open AccessGlobal perspectives on lupus nephritis: a review of clinical trials and therapeutic innovations
Background and objectives: Lupus nephritis (LN) remains a leading cause of morbidity and mortality in systemic lupus erythematosus (SLE). Although recent years have witnessed the approval of several targeted therapies, achieving long-term, drug-free remission remains challenging. This commentary evaluates the global landscape of interventional LN clinical trials from 2001 to 2026 to identify emerging trends and strategic gaps in drug development. Methods: We analyzed 200 interventional pharmacological trials retrieved from three major global registries: ClinicalTrials.gov , Chinadrugtrials.org , and ISRCTN. Trials were systematically categorized by study phase, geographic distribution, and therapeutic mechanism, with data synthesized to reflect the transition from non-specific immunosuppression to precision-targeted approaches. Key findings: Our analysis indicates an accelerating trend in Phase II/III trials, with a notable geographic shift toward the Asia-Pacific region. We identify a diversification of therapeutic targets beyond B-cell depletion (e.g., obinutuzumab) to include complement inhibitors, intracellular signaling blockers (BTK and JAK inhibitors), and novel immune-reset strategies such as CAR-T therapy. Despite these innovations, complete renal response rates in pivotal trials often plateau at 40-50%, suggesting a persistent “ceiling effect”. Conclusion and implications: To break current therapeutic plateaus, future research must prioritize: (1) integrating pharmacogenomics (e.g., CYP3A5 and TPMT genotyping) for personalized drug selection; (2) developing steroid-fast-tapering or steroid-free induction protocols to minimize toxicity; and (3) validating real-time molecular biomarkers to replace lagging clinical indicators. This data-driven perspective provides a practical framework for refining trial designs and achieving precision medicine in LN.
- Open Access
- 1 October 2024
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 17, 4595-4605
Ruanjian Qingmai Granules for the Treatment of Early Symptomatic Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Protocol
Purpose: Peripheral arterial disease (PAD) is a chronic ischemic disease caused by atherosclerosis of the lower extremities, with early clinical symptoms manifesting mainly as intermittent claudication. Current treatment of PAD is based on the control of cardiovascular risk factors. However, even vasoactive drugs are not ideal for improving ischemic symptoms in the lower limbs of PAD patients. Ruanjian Qingmai granules, derived from the classic formula of the late Professor Jiuyi Xi, a famous traditional Chinese medicine doctor in Shanghai, have good clinical efficacy in the treatment of the pattern of blood vessel stasis and obstruction of PAD and have been used by more than 600,000 PAD patients over the past three decades. This study aims to evaluate the efficacy and safety of Ruanjian Qingmai granules in patients with symptomatic PAD. Patients and methods: A prospective, center-randomized, double-blind, placebo-controlled clinical trial will be conducted at 9 grade A tertiary hospitals in Shanghai. It is anticipated that 250 patients with early symptomatic PAD will be recruited and randomized to the control and intervention groups (1:1 ratio of central randomization). Subjects will be treated with Ruanjian Qingmai granules or placebo at 6 g twice daily for 16 weeks. The primary efficacy indicators are the pain-free walking distance and maximum walking distance. The secondary efficacy indicators are the ankle-brachial index, walking impairment questionnaire, quality of life score, and Chinese medicine syndrome score. Conclusion: Positive results from this study will demonstrate the efficacy and safety of Ruanjian Qingmai granules in improving ischemic symptoms in patients with symptomatic PAD. Clinical Registration: This study has been registered with the Chinese Clinical Trials Registry (ChiCTR2200056109, Date: 02/01/2022, https://www.chictr.org.cn/showproj.html?proj=150982).
- 1 October 2024
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 17, 4595-4605
Open AccessRuanjian Qingmai Granules for the Treatment of Early Symptomatic Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Protocol
Purpose: Peripheral arterial disease (PAD) is a chronic ischemic disease caused by atherosclerosis of the lower extremities, with early clinical symptoms manifesting mainly as intermittent claudication. Current treatment of PAD is based on the control of cardiovascular risk factors. However, even vasoactive drugs are not ideal for improving ischemic symptoms in the lower limbs of PAD patients. Ruanjian Qingmai granules, derived from the classic formula of the late Professor Jiuyi Xi, a famous traditional Chinese medicine doctor in Shanghai, have good clinical efficacy in the treatment of the pattern of blood vessel stasis and obstruction of PAD and have been used by more than 600,000 PAD patients over the past three decades. This study aims to evaluate the efficacy and safety of Ruanjian Qingmai granules in patients with symptomatic PAD. Patients and methods: A prospective, center-randomized, double-blind, placebo-controlled clinical trial will be conducted at 9 grade A tertiary hospitals in Shanghai. It is anticipated that 250 patients with early symptomatic PAD will be recruited and randomized to the control and intervention groups (1:1 ratio of central randomization). Subjects will be treated with Ruanjian Qingmai granules or placebo at 6 g twice daily for 16 weeks. The primary efficacy indicators are the pain-free walking distance and maximum walking distance. The secondary efficacy indicators are the ankle-brachial index, walking impairment questionnaire, quality of life score, and Chinese medicine syndrome score. Conclusion: Positive results from this study will demonstrate the efficacy and safety of Ruanjian Qingmai granules in improving ischemic symptoms in patients with symptomatic PAD. Clinical Registration: This study has been registered with the Chinese Clinical Trials Registry (ChiCTR2200056109, Date: 02/01/2022, https://www.chictr.org.cn/showproj.html?proj=150982).
- Open Access
- 27 June 2024
- Published by Elsevier in Pharmacological Research
- Vol. 206, 107276
Action and therapeutic targets of myosin light chain kinase, an important cardiovascular signaling mechanism
- 27 June 2024
- Published by Elsevier in Pharmacological Research
- Vol. 206, 107276
Open AccessAction and therapeutic targets of myosin light chain kinase, an important cardiovascular signaling mechanism
- Open Access
- 29 December 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (52) , e36762
Exploring the potential mechanism of Simiao Yongan decoction in the treatment of diabetic peripheral vascular disease based on network pharmacology and molecular docking technology
The study aims to investigate the potential action targets and molecular mechanisms of Simiao Yongan decoction (SMYAD) in treating diabetic peripheral vascular disease (DPVD) by utilizing network pharmacology analysis and molecular docking technology. The components and targets of SMYAD were screened using the TCMSP database, while DPVD-related genes were obtained from the GeneCards, OMIM, and Disgenet databases. After intersecting the gene sets, a Protein-Protein Interaction (PPI) network was established, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were carried out. The practical chemical components and core targets identified were molecularly docked using AutoDock software. A total of 126 active compounds were screened from which 25 main components included quercetin, rutoside, hesperidin, naringin, and β-sitosterol were determined to be the active components most associated with the core targets. A total of 224 common target genes were obtained. Among them, JUN, AKT1, MAPK3, TP53, STAT3, RELA, MAPK1, FOS, and others are the expected core targets of traditional Chinese medicine. The top-ranked GO enrichment analysis results included 727 biological processes (BP), 153 molecular functions (MF), and 102 cellular components (CC). KEGG pathway enrichment analysis involved mainly 178 signaling pathways, such as cancer signaling pathway, AGE-RAGE signaling pathway, interleukin-17 signaling pathway, tumor necrosis factor signaling pathway, endocrine resistance signaling pathway, cell aging signaling pathway, and so on. The molecular docking results demonstrate that the principal chemical components of SMYAD exhibit considerable potential for binding to the core targets. SMYAD has the potential to treat DPVD through various components, targets, and pathways. Its mechanism of action requires further experimental investigation.
- 29 December 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (52) , e36762
Open AccessExploring the potential mechanism of Simiao Yongan decoction in the treatment of diabetic peripheral vascular disease based on network pharmacology and molecular docking technology
The study aims to investigate the potential action targets and molecular mechanisms of Simiao Yongan decoction (SMYAD) in treating diabetic peripheral vascular disease (DPVD) by utilizing network pharmacology analysis and molecular docking technology. The components and targets of SMYAD were screened using the TCMSP database, while DPVD-related genes were obtained from the GeneCards, OMIM, and Disgenet databases. After intersecting the gene sets, a Protein-Protein Interaction (PPI) network was established, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were carried out. The practical chemical components and core targets identified were molecularly docked using AutoDock software. A total of 126 active compounds were screened from which 25 main components included quercetin, rutoside, hesperidin, naringin, and β-sitosterol were determined to be the active components most associated with the core targets. A total of 224 common target genes were obtained. Among them, JUN, AKT1, MAPK3, TP53, STAT3, RELA, MAPK1, FOS, and others are the expected core targets of traditional Chinese medicine. The top-ranked GO enrichment analysis results included 727 biological processes (BP), 153 molecular functions (MF), and 102 cellular components (CC). KEGG pathway enrichment analysis involved mainly 178 signaling pathways, such as cancer signaling pathway, AGE-RAGE signaling pathway, interleukin-17 signaling pathway, tumor necrosis factor signaling pathway, endocrine resistance signaling pathway, cell aging signaling pathway, and so on. The molecular docking results demonstrate that the principal chemical components of SMYAD exhibit considerable potential for binding to the core targets. SMYAD has the potential to treat DPVD through various components, targets, and pathways. Its mechanism of action requires further experimental investigation.